Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Abstract

Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.).

Keywords

OsimertinibT790MMedicineOncologyEpidermal growth factor receptorLung cancerGefitinibInternal medicineHazard ratioProgression-free survivalTyrosine kinaseCancer researchOverall survivalCancerErlotinibReceptorConfidence interval

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Diagnosing and Managing Advanced Chronic Myeloid Leukemia

Michael W. Deininger

Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural h...

2015 American Society of Clinical Oncology... 28 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Publication Info

Year: 2019
Type: article
Volume: 382
Issue: 1
Pages: 41-50
Citations: 2577
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2577

OpenAlex

Cite This

APA Style

                            
                                
                                    Suresh S. Ramalingam, 
                                
                                    Johan Vansteenkiste, 
                                
                                    David Planchard
                                
                                et al.
                            
                            (2019). 
                            Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC. 
                            New England Journal of Medicine
                            , 382
                            (1)
                            , 41-50.
                            https://doi.org/10.1056/nejmoa1913662
                        

Identifiers

DOI: 10.1056/nejmoa1913662